Zevra Therapeutics, Inc. press release ( ZVRA ): Q4 GAAP EPS of $0.19 beats by $0.14 . Revenue of $34.1M (+184.2% Y/Y) beats by $6.05M . More on Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Zevra Therapeutics: Asymmet...
Zevra Therapeutics, Inc. press release ( ZVRA ): Q4 GAAP EPS of $0.19 beats by $0.14 . Revenue of $34.1M (+184.2% Y/Y) beats by $6.05M . More on Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market Zevra Therapeutics, Inc. Q4 2025 Earnings Preview Zevra Therapeutics appoints Justin Renz as CFO
narvo vexar/iStock via Getty Images Investment Overview I have been covering CRISPR Therapeutics AG ( CRSP ), the Zug, Switzerland-based gene therapy developer that leverages the Nobel Prize-winning CRISPR /Cas9 gene editing biotechnology pioneered by Dr. Emmanuelle Charpentier, a scientific co-founder of the company, and others, since I first published a note on the company in May 2021, issuing a...
narvo vexar/iStock via Getty Images Investment Overview I have been covering CRISPR Therapeutics AG ( CRSP ), the Zug, Switzerland-based gene therapy developer that leverages the Nobel Prize-winning CRISPR /Cas9 gene editing biotechnology pioneered by Dr. Emmanuelle Charpentier, a scientific co-founder of the company, and others, since I first published a note on the company in May 2021, issuing a Buy recommendation. I'm sad to report that, nearly five years on, CRISPR Therapeutics stock has fallen in value by >50%. Its share price (at the time of writing) is $58, and its market cap valuation is $5.5bn. For the past five years, I'd say the company's share price has undergone a series of mini-peaks and troughs, reaching highs of $84 in July 2022, $84 in February 2025, shortly after its first commercial product, the sickle cell disease ("SCD") /transfusion-dependent beta thalassemia ("TDT") therapy Casgevy, was approved, and $75 in October last year, and lows of <$40 in October 2023 and March 2025. The highest value the stock has reached since the company's IPO in 2017 is ~$165 per share, with gains triggered at that time by the news that its co-development partner on Casgevy, Vertex Pharmaceuticals Incorporated ( VRTX ), would pay $900m to increase its share of future exa-cel (now Casgevy) profits from 50% to 60% (with an additional $200m payable upon the drug's approval). In fact, it is hard to think of CRISPR Therapeutics without thinking of Vertex, and vice versa, which is why it may not have surprised many people when rumors began to circulate towards the end of February that CRISPR Therapeutics may be acquired and that Vertex was the likeliest buyer. After the news was reported, CRISPR Therapeutics stock jumped from ~$54 to >$60. Conversely, Vertex stock was trading at $497 per share at the time and now trades at $459 per share. I have repeatedly made the bull case for CRISPR Therapeutics, for Casgevy and its ability to one day generate "blockbuster" revenues, a...
Hewlett Packard Enterprise press release ( HPE ): Q1 Non-GAAP EPS of $0.65 beats by $0.06 . Revenue of $9.3B (+18.5% Y/Y) misses by $50M . Networking revenue was $2.7 billion, up 151.5% from the prior-year period, with 23.7% operating profit margin, compared to 29.7% from the prior-year period. This segment incorporates our former Intelligent Edge segment and Juniper Networks. Within Networking, r...
Hewlett Packard Enterprise press release ( HPE ): Q1 Non-GAAP EPS of $0.65 beats by $0.06 . Revenue of $9.3B (+18.5% Y/Y) misses by $50M . Networking revenue was $2.7 billion, up 151.5% from the prior-year period, with 23.7% operating profit margin, compared to 29.7% from the prior-year period. This segment incorporates our former Intelligent Edge segment and Juniper Networks. Within Networking, revenue from: Campus & Branch was $1.2 billion, up 42.0% from the prior-year period. Data Center Networking was $444 million, up 382.6% from the prior-year period. Security was $255 million, up 114.3% from the prior-year period. Routing was $780 million, compared to $1 million in the prior-year period. Cloud & AI revenue was $6.3 billion, down 2.7% from the prior-year period, with 10.2% operating profit margin, compared to 8.4% from the prior-year period. This segment consolidates HPE’s server, storage, and financial services businesses, representing a new financial segment for FY26. Within Cloud & AI, revenue from: Server was $4.2 billion, down 2.7% from the prior-year period. Storage was $1.1 billion, up 0.6% from the prior-year period. Financial Services was $0.9 billion, up 0.3% from the prior-year period. Fiscal 2026 Second Quarter Outlook HPE estimates revenue to be in the range of $9.6 billion to $10.0 billion vs consensus of $9.56B. HPE estimates GAAP diluted net EPS to be in the range of $0.09 to $0.13 and non-GAAP diluted net EPS to be in the range of $0.51 to $0.55 vs consensus of $0.53. Fiscal 2026 second quarter non-GAAP diluted net EPS estimate excludes net after-tax adjustments of approximately $0.42 per diluted share, primarily related to amortization of intangible assets, stock-based compensation expense, acquisition, disposition and other charges, and cost reduction program. Fiscal 2026 Full Year Outlook HPE is reaffirming its FY26 revenue growth outlook range of 17% to 22%, as previously provided at our Securities Analyst Meeting. HPE is raising revenue gr...
Dario Amodei, chief executive officer of Anthropic, at the AI Impact Summit in New Delhi, India, on Thursday, Feb. 19, 2026. Ruhani Kaur | Bloomberg | Getty Images Last August, Pentagon technology chief Emil Michael , a former Uber executive and attorney, took on the added role of overseeing the Defense Department's artificial intelligence portfolio. A month earlier, Anthropic had been awarded a $...
Dario Amodei, chief executive officer of Anthropic, at the AI Impact Summit in New Delhi, India, on Thursday, Feb. 19, 2026. Ruhani Kaur | Bloomberg | Getty Images Last August, Pentagon technology chief Emil Michael , a former Uber executive and attorney, took on the added role of overseeing the Defense Department's artificial intelligence portfolio. A month earlier, Anthropic had been awarded a $200 million DOD contract that expanded its work with the agency. "I said, 'I just want to see the contracts,'" Michael told the All-In Podcast on Friday, reflecting on his early days managing the AI portfolio. "You know, the old lawyer in me." Michael's request kicked off a months-long review process that culminated in the Defense Department banning Anthropic's technology, leaving the military without its hand-picked AI models to operate in the most sensitive environments. In an extraordinary move, the DOD designated Anthropic a supply chain risk , a label that's historically only been applied to foreign adversaries. It will require defense vendors and contractors to certify that they don't use the company's models in their work with the Pentagon. Anthropic sued the Trump administration on Monday, calling the government's actions "unprecedented and unlawful," and claiming that they are "harming Anthropic irreparably," putting hundreds of millions of dollars worth of contracts in jeopardy. The DOD's sudden reversal came as a shock to many officials in Washington who viewed Anthropic's models as superior — they were the first to be deployed in the agency's classified networks — and championed the company's ability to integrate with existing defense contractors like Palantir . The decision was all the more puzzling since the Trump administration had threatened during negotiations to invoke the Defense Production Act, which could have forced Anthropic to grant the military access to its technology. "I don't know how those two things can both be true in reality," said Mark Dalto...
The S&P 500 is the world's most widely followed equity index, and the world of exchange-traded funds (ETFs) confirms as much. Each of the top three U.S.-listed ETFs, including the Vanguard S&P 500 ETF (VOO +0.87%), tracks the S&P 500. Led by the Vanguard fund at $865 billion, those three ETFs combine for a staggering $2.28 trillion in assets under management (AUM). The other members of that trio a...
The S&P 500 is the world's most widely followed equity index, and the world of exchange-traded funds (ETFs) confirms as much. Each of the top three U.S.-listed ETFs, including the Vanguard S&P 500 ETF (VOO +0.87%), tracks the S&P 500. Led by the Vanguard fund at $865 billion, those three ETFs combine for a staggering $2.28 trillion in assets under management (AUM). The other members of that trio are the iShares Core S&P 500 ETF (IVV +0.88%) and the State Street SPDR S&P 500 ETF (SPY +0.91%). The Vanguard ETF's AUM lead over the second-place iShares fund is sizable at north of $124 billion, but there are other details for investors, particularly those new to the game, to consider. Let's look at three important ones here. 1. S&P 500 ETFs are diverse...sort of This isn't an indictment of the Vanguard fund, because what follows is true of all the ETFs mentioned, but the reality is that S&P 500 index funds aren't as diverse as they used to be or as diverse as some market participants expect these products to be. Translation: The Vanguard ETF and its brethren allocate significant portions of their lineups to a small number of stocks. As of the end of January, the top five holdings in the Vanguard fund combined for approximately 27% of its weight. By the S&P 500's historical standards, that level of concentration is elevated. As for how that situation materialized, it's the result of the index's weighting components based on market capitalization. Put simply, as a stock's market cap increases, it takes on a larger slice of a cap-weighted pie, such as the S&P 500. 2. It's a blend ETF, or is it? Experienced investors know about style, and that doesn't mean the GQ or Vogue type. When it comes to ETFs or other funds, they're classified by a combination of market capitalization and style, such as growth, value, or a blend fund. This Vanguard ETF and its S&P 500 peers are classified as large-cap blend funds, but are they really? Due to the aforementioned market-cap-weighted meth...
Key Points The Vanguard S&P 500 ETF is the largest ETF in the world. It's a practical, cost-effective way to get exposure to the stock market. Believe it or not, it’s not the cheapest ETF out there. 10 stocks we like better than Vanguard S&P 500 ETF › The S&P 500 is the world's most widely followed equity index, and the world of exchange-traded funds (ETFs) confirms as much. Each of the top three ...
Key Points The Vanguard S&P 500 ETF is the largest ETF in the world. It's a practical, cost-effective way to get exposure to the stock market. Believe it or not, it’s not the cheapest ETF out there. 10 stocks we like better than Vanguard S&P 500 ETF › The S&P 500 is the world's most widely followed equity index, and the world of exchange-traded funds (ETFs) confirms as much. Each of the top three U.S.-listed ETFs, including the Vanguard S&P 500 ETF (NYSEMKT: VOO), tracks the S&P 500. Led by the Vanguard fund at $865 billion, those three ETFs combine for a staggering $2.28 trillion in assets under management (AUM). The other members of that trio are the iShares Core S&P 500 ETF (NYSEMKT: IVV) and the State Street SPDR S&P 500 ETF (NYSEMKT: SPY). Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The Vanguard ETF's AUM lead over the second-place iShares fund is sizable at north of $124 billion, but there are other details for investors, particularly those new to the game, to consider. Let's look at three important ones here. 1. S&P 500 ETFs are diverse...sort of This isn't an indictment of the Vanguard fund, because what follows is true of all the ETFs mentioned, but the reality is that S&P 500 index funds aren't as diverse as they used to be or as diverse as some market participants expect these products to be. Translation: The Vanguard ETF and its brethren allocate significant portions of their lineups to a small number of stocks. As of the end of January, the top five holdings in the Vanguard fund combined for approximately 27% of its weight. By the S&P 500's historical standards, that level of concentration is elevated. As for how that situation materialized, it's the result of the index's weighting components based on market capitalization. Put simply, as a stock's market cap increases, it takes o...
The US told its Group of Seven partners that Russia sanctions relief would be temporary as it reacts to spiking energy prices amid the war in Iran, the European Union’s economy chief said. The assurances came Monday during a call of G-7 finance ministers, held shortly after the Trump administration granted India a waiver to buy Russian oil held at sea. The US was “emphasizing” that the India decis...
The US told its Group of Seven partners that Russia sanctions relief would be temporary as it reacts to spiking energy prices amid the war in Iran, the European Union’s economy chief said. The assurances came Monday during a call of G-7 finance ministers, held shortly after the Trump administration granted India a waiver to buy Russian oil held at sea. The US was “emphasizing” that the India decision was “very much contained both in terms of time and scope of the measures,” said EU Economy Commissioner Valdis Dombrovskis , who joined the call. “They do not expect substantial impact of this on Russian oil revenues,” he added, speaking during a Monday night press conference. The India waiver left Europeans anxious that the US may be loosening its restrictions on Russia just as just as Moscow’s economy shows signs of significant strain. US Treasury Secretary Scott Bessent had also indicated more sanctions could be lifted. But Dombrovskis stressed that the US was “broadly aligned” with Europe’s desire to keep the economic pressure on Russia, despite the Iran war driving up oil and gas prices. Russian oil revenues collapsed earlier this year due to weaker global prices and penalties that created steep discounts for the nation’s crude. Read More: Russian Oil Revenues Plunge to Five-Year Low on Sanctions, Ruble But oil prices are now reaching heights not seen since Russia launched its full-scale war in Ukraine, giving Moscow a chance to grow its revenues. “It’s important that we do not now ease the pressure on Russia and do not help Russia to fill its war chest using this situation of elevated oil and gas prices,” Dombrovskis said. Read More: Russia Gets a Chance to Boost Oil Income as War Disrupts Hormuz
Archer Aviation ( ACHR ) announced that it will work with its partners, including the Texas Department of Transportation, the Florida Department of Transportation, and the Port Authority of New York and New Jersey, to prepare for flights of its Midnight aircraft under the White House eVTOL Integration Pilot Program. The company's plans include standing up local operating teams, infrastructure, and...
Archer Aviation ( ACHR ) announced that it will work with its partners, including the Texas Department of Transportation, the Florida Department of Transportation, and the Port Authority of New York and New Jersey, to prepare for flights of its Midnight aircraft under the White House eVTOL Integration Pilot Program. The company's plans include standing up local operating teams, infrastructure, and procedures to ensure safe, measured eVTOL deployment. Looking ahead, Archer ( ACHR ) expects the effort to generate valuable operational experience that will help inform future deployments in the U.S. and drive public acceptance, including as it continues to prepare for air taxi operations in Los Angeles for the 2028 Olympic Games. Midnight is Archer's ( ACHR ) piloted electric air taxi designed to carry up to four passengers while producing less noise and emissions than a traditional helicopter. Midnight is built with redundant systems across the aircraft, including 12 total engines and propellers, allowing the eVTOL player to target similar levels of safety as commercial airliners. Shares of Archer Aviation ( ACHR ) ended the Monday trading session up 4.3%. More on Archer Aviation Archer Aviation: What We Learned From FY 2025 Results Archer Aviation: Timelines Continue To Slide Archer Aviation Inc. (ACHR) Q4 2025 Earnings Call Transcript Joby and Archer Aviation among eight firms selected for DOT air taxi pilot program Archer outlines path to 2028 Olympics air taxi debut while advancing UAE and U.S. commercialization
Xenon Pharmaceuticals ( XENE ) on Monday said it has begun an underwritten public offering of $500 million of its common shares under an existing shelf registration statement. The company said it plans to grant underwriters a 30-day option to buy up to an additional $75 million of shares at the public offering price, excluding underwriting discounts and commissions. The offering is subject to mark...
Xenon Pharmaceuticals ( XENE ) on Monday said it has begun an underwritten public offering of $500 million of its common shares under an existing shelf registration statement. The company said it plans to grant underwriters a 30-day option to buy up to an additional $75 million of shares at the public offering price, excluding underwriting discounts and commissions. The offering is subject to market and other conditions, and there is no assurance on whether or when it will be completed. XENE -1.83% after hours to $61.47. Source: Press Release More on Xenon Pharma Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures - Slideshow Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked Xenon announces positive topline data from phase 3 X-TOLE2 study of azetukalner Seeking Alpha’s Quant Rating on Xenon Pharma
As oil prices surge, energy stocks could reclaim their crown as the market's leaders, if history is any precedence. West Texas Intermediate crude futures jumped to a high of more than $119 in overnight trading as tensions in the Middle East escalated. The Dow Jones Industrial Average fell 886 points at its low on Monday. Stocks ultimately rebounded into positive territory as President Donald Trump...
As oil prices surge, energy stocks could reclaim their crown as the market's leaders, if history is any precedence. West Texas Intermediate crude futures jumped to a high of more than $119 in overnight trading as tensions in the Middle East escalated. The Dow Jones Industrial Average fell 886 points at its low on Monday. Stocks ultimately rebounded into positive territory as President Donald Trump said the war could be over soon. Oil prices have popped as the effective closure of the key Strait of Hormuz passageway has disrupted global energy supplies. Iraq has seen production from its main southern oilfields fall 70%, according to Reuters , while Kuwait has announced cuts . Oil last crossed the $100 per barrel price threshold on March 1, 2022, in the days following Russia's invasion of Ukraine. Prices did not cross below the level for good until July 19, 2022. CNBC looked at stocks in the S & P 500 that were the best and worst performers during this stretch for any hints of the market leaders this time around. Unsurprisingly, energy stocks outperformed last time oil prices surged above $100. Of the five stocks that outperformed the most from March to July 2022, four belonged to the energy industry. Similarly, these names have already bucked the stock market's year-to-date decline, with shares of Texas Pacific Land up 87% in 2026. Valero Energy and Occidental Petroleum have both surged more than 30%, while EQT is up nearly 16% in 2026. On the other hand, the worst performers during this stretch in 2022 were more consumer-tied names, such as Carvana and Royal Caribbean Group . Shares of Carvana have already plunged 26% this year, while Royal Caribbean Group is down almost 1%. Cruise operator Royal Caribbean fell on Monday alongside other travel stocks, as rising oil prices stirred up worries that drive fuel costs higher and eat into profits. Month to date, the stock was last trading 11% lower.
In trading on Monday, shares of AllianzGI Convertible & Income Fund (Symbol: NCV) crossed below their 200 day moving average of $15.00, changing hands as low as $14.91 per share. AllianzGI Convertible & Income Fund shares are currently trading down about 2.8% on the day. The chart below shows the one year performance of NCV shares, versus its 200 day moving average: Looking at the chart above, NCV...
In trading on Monday, shares of AllianzGI Convertible & Income Fund (Symbol: NCV) crossed below their 200 day moving average of $15.00, changing hands as low as $14.91 per share. AllianzGI Convertible & Income Fund shares are currently trading down about 2.8% on the day. The chart below shows the one year performance of NCV shares, versus its 200 day moving average: Looking at the chart above, NCV's low point in its 52 week range is $11.5104 per share, with $16.70 as the 52 week high point — that compares with a last trade of $14.99. Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
United Nations Assistant Secretary General Kirsi Madi discusses the importance of women's economic empowerment, saying that gender equality is 'not only a basic human right, not only the right thing to do, [but] it's also smart business." She talks with Katie Greifeld and Romaine Bostick on "The Close." (Source: Bloomberg)
United Nations Assistant Secretary General Kirsi Madi discusses the importance of women's economic empowerment, saying that gender equality is 'not only a basic human right, not only the right thing to do, [but] it's also smart business." She talks with Katie Greifeld and Romaine Bostick on "The Close." (Source: Bloomberg)
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels. Exited 2025 with $36.8 million of cash an...
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels. Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth. Benefits infrastructure on track to cover approximately 220 million Americans in second quarter; women’s health offering seeing strong early patient growth. Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the fourth quarter and year ended December 31, 2025. Management Commentary “LifeMD delivered strong fourth quarter results across all business lines and is entering its next phase of growth,” said Justin Schreiber, Chairman and CEO of LifeMD. “Our strategy of building a trusted and sustainable platform for virtual healthcare delivery is gaining momentum. Our weight management business is seeing record patient sign-ups in the first quarter at attractive acquisition costs. More than 100 million Americans are clinically eligible for GLP-1 therapy, yet only a fraction are currently being treated—a generational opportunity. Subsequent to year end, we launched oral Wegovy to help patients overcome real barriers around cost, access, and ongoing clinical support. With multiple catalysts ahead—including Medicare coverage for GLP-1 medications, expanded collaborations with GLP-1 manufacturers, and an infrastructure that supports both self-pay and insurance—LifeMD is uniquely positioned for long-term leadership in this transformative market. “Beyond weight management, our highly differentiated specialty offerings continue to scale. Rex MD, our men’...
Net Asset Value of $8.09 Per Share as of December 31, 2025 Recent 2026 Portfolio Company Financings Expected to Add an Estimated $5.00 - $6.50 to Net Asset Value Per Share NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31...
Net Asset Value of $8.09 Per Share as of December 31, 2025 Recent 2026 Portfolio Company Financings Expected to Add an Estimated $5.00 - $6.50 to Net Asset Value Per Share NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. Net assets totaled approximately $205.3 million, or $8.09 per share, at December 31, 2025, as compared to $9.23 per share, at September 30, 2025 and $6.68 per share at December 31, 2024. “2025 was a year of strong performance across our portfolio, underscoring the continued execution and value creation at several of our largest investments. That momentum has continued into 2026, with a number of our portfolio companies having completed, or in the process of completing, significant financings,” said Mark Klein, Chairman and Chief Executive Officer of SuRo Capital. “Based on indications available today, and assuming each of the financings closes and the remainder of our portfolio remains at its December 31, 2025 valuation, we believe these financings could contribute approximately $5.00 to $6.50 per share to our current net asset value. As these developments arose in 2026, they are not reflected in our December 31, 2025 net asset value.” Mr. Klein continued, “We also remain active in deploying capital into high-conviction opportunities aligned with our core investment themes, including our recent investment in TensorWave, which further expands our exposure to AI infrastructure.” “As we look ahead, we are encouraged by the continued progress across our portfolio. We believe our strategy of investing in category-defining companies, including those building technologies that are transforming how businesses operate, positions SuRo Capital to create substantial long-term value for shareholders. We remain focused on disciplined execution, including realizing gains and retur...
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc...
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025. "We made significant strides advancing our pipeline in the past year, and 2026 has already delivered a meaningful milestone with positive Phase 1 results for SEP-631,” said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. “These results demonstrate clinical proof-of-mechanism and validate the ability of our Native Complex Platform® to uncover novel mechanisms of action and rapidly generate differentiated oral small molecules for historically challenging GPCRs. With SEP-479 approaching Phase 1 initiation in the coming months, SEP-631 poised for Phase 2 development in the second half of the year, and additional programs progressing behind them, we believe 2026 will be a year of strong progress for Septerna and for the patients we are committed to serving.” Recent Pipeline Progress and Anticipated Milestones SEP-631 MRGPRX2 NAM for Mast Cell Diseases: In March 2026, Septerna presented positive results from its Phase 1 clinical trial evaluating SEP-631, its potent, selective and insurmountable oral small molecule MRGPRX2 negative allosteric modulator (NAM) and outlined its initial Phase 2 development strategy. Key findings include: Safety: SEP-631 was well-tolerated at all doses studied with an adverse event profile comparable to placebo. Pharmacokinetics (PK): SEP-...
SHAKOPEE, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2025. ($ in thousands, except per share data and percentages) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 Change 2025 2024 Change Net revenues $1...
SHAKOPEE, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2025. ($ in thousands, except per share data and percentages) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 Change 2025 2024 Change Net revenues $12,446 $11,978 3.9% $59,568 $61,562 (3.2%) Net income (loss) (1) ($390) ($1,245) (68.7%) ($529) $2,113 (125.1%) Adjusted EBITDA (2) $2,288 $1,497 52.8% $9,410 $10,805 (12.9%) Basic EPS ($0.08) ($0.25) (68.0%) ($0.10) $0.42 (123.8%) Diluted EPS ($0.08) ($0.25) (68.0%) ($0.10) $0.42 (123.8%) (1) Net income and basic and diluted EPS for the twelve months ended December 31, 2024, benefited from a $1.7 million gain related to the transfer of land to a new joint venture. (2) Adjusted EBITDA, a non-GAAP measure, excludes certain items from net income, a GAAP measure. Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results. Definitions, disclosures, and reconciliations of non-GAAP financial information are included later in the release. Adjusted EBITDA margin is Adjusted EBITDA as a percentage of net revenues. Management Commentary Randy Sampson, President and Chief Executive Officer of Canterbury Park, commented, “Fourth quarter results are consistent with historical seasonality and conclude a year of transformation and diversification. Fourth quarter revenue increased 3.9% to $12.4 million, driven largely by 5.4% growth in Casino revenue. Visitation rose in the fourth quarter, and we remain focused on increasing casino traffic through our expanded VIP programs as well as enhanced advertising and marketing initiatives. Food and Beverage revenue grew slightly in the quarter, while Pari-Mutuel revenues declined slightly because of fewer races compared to last year. Adjusted EBITDA of $2.3 million rose 53% year-ove...